Sangeeta Jethwa

Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival

Bernard Escudier, Joaquim Bellmunt, Sylvie Négrier et al. · Journal of Clinical Oncology · 2010 · 808 citations

Medicine, Oncology, Pharmacotherapy +12

Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-α2a (IFN) in metastatic renal cell carcinoma (mRCC)

Bernard Escudier, Joaquim Bellmunt, S. Négrier et al. · Journal of Clinical Oncology · 2009 · 88 citations

Medicine, Oncology, Pharmacotherapy +16

Development of the SMA independence scale–upper limb module (SMAIS–ULM): A novel scale for individuals with Type 2 and non-ambulant Type 3 SMA

Dylan Trundell, Anne Skalicky, Hannah Staunton et al. · Journal of the Neurological Sciences · 2021 · 35 citations

Medicine, Rehabilitation Medicine, Functional Movement Assessment +16

A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN

Bohuslav Melichar, Sergio Bracarda, B. Yа. Alekseev et al. · Annals of Oncology · 2013 · 31 citations

Medicine, Oncology, Pharmacology +13